Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT00310037. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase II trial studies how well bortezomib works when given after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with an autologous stem cell transplant may allow more chemotherapy to be given so that more cancer cells are killed. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib after combination chemotherapy, monoclonal antibody therapy, and an autologous stem cell transplant may kill any remaining cancer cells or keep the cancer from coming back.
Study identification
- NCT ID
- NCT00310037
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 69 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Nov 30, 2013
- Completion
- May 31, 2022
- Last update posted
- Oct 27, 2025
2006 – 2022
United States locations
- U.S. sites
- 48
- U.S. states
- 8
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| Illinois CancerCare - Bloomington | Bloomington | Illinois | 61701 | — |
| St. Joseph Medical Center | Bloomington | Illinois | 61701 | — |
| Graham Hospital | Canton | Illinois | 61520 | — |
| Illinois CancerCare - Canton | Canton | Illinois | 61520 | — |
| Illinois CancerCare - Carthage | Carthage | Illinois | 62321 | — |
| Memorial Hospital | Carthage | Illinois | 62321 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637-1470 | — |
| Eureka Community Hospital | Eureka | Illinois | 61530 | — |
| Illinois CancerCare - Eureka | Eureka | Illinois | 61530 | — |
| Galesburg Clinic, PC | Galesburg | Illinois | 61401 | — |
| Illinois CancerCare - Galesburg | Galesburg | Illinois | 61401 | — |
| Illinois CancerCare - Havana | Havana | Illinois | 62644 | — |
| Mason District Hospital | Havana | Illinois | 62644 | — |
| Illinois CancerCare - Kewanee Clinic | Kewanee | Illinois | 61443 | — |
| Illinois CancerCare - Macomb | Macomb | Illinois | 61455 | — |
| McDonough District Hospital | Macomb | Illinois | 61455 | — |
| Illinois CancerCare - Monmouth | Monmouth | Illinois | 61462 | — |
| OSF Holy Family Medical Center | Monmouth | Illinois | 61462 | — |
| BroMenn Regional Medical Center | Normal | Illinois | 61761 | — |
| Community Cancer Center | Normal | Illinois | 61761 | — |
| Illinois CancerCare - Community Cancer Center | Normal | Illinois | 61761 | — |
| Community Hospital of Ottawa | Ottawa | Illinois | 61350 | — |
| Oncology Hematology Associates of Central Illinois, PC - Ottawa | Ottawa | Illinois | 61350 | — |
| Illinois CancerCare - Pekin | Pekin | Illinois | 61603 | — |
| Proctor Hospital | Peoria | Illinois | 61614 | — |
| CCOP - Illinois Oncology Research Association | Peoria | Illinois | 61615 | — |
| Oncology Hematology Associates of Central Illinois, PC - Peoria | Peoria | Illinois | 61615 | — |
| Methodist Medical Center of Illinois | Peoria | Illinois | 61636 | — |
| OSF St. Francis Medical Center | Peoria | Illinois | 61637 | — |
| Illinois CancerCare - Peru | Peru | Illinois | 61354 | — |
| Illinois Valley Community Hospital | Peru | Illinois | 61354 | — |
| Illinois CancerCare - Princeton | Princeton | Illinois | 61356 | — |
| Perry Memorial Hospital | Princeton | Illinois | 61356 | — |
| Illinois CancerCare - Spring Valley | Spring Valley | Illinois | 61362 | — |
| Dana-Farber/Brigham and Women's Cancer Center | Boston | Massachusetts | 02115 | — |
| Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St Louis | Missouri | 63110 | — |
| Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756-0002 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| Monter Cancer Center of the North Shore-LIJ Health System | Lake Success | New York | 11042 | — |
| CCOP - North Shore University Hospital | Manhasset | New York | 11030 | — |
| Don Monti Comprehensive Cancer Center at North Shore University Hospital | Manhasset | New York | 11030 | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11040 | — |
| SUNY Upstate Medical University Hospital | Syracuse | New York | 13210 | — |
| Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | 27599-7295 | — |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1096 | — |
| Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210-1240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00310037, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2025 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00310037 live on ClinicalTrials.gov.